2021 Çѱ¹Á¤½Å½ÅüÀÇÇÐ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-12-17±³À°ÀÏÀÚ : 2021-12-17
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ,´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2021 Çѱ¹Á¤½Å½ÅüÀÇÇÐ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ
´ã´çÀÚ : °íÀº¾ç
¿¬¶ôó : 070-4888-5731
À̸ÞÀÏ :
sericonf@daum.net ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 10 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 09:10~09:35 µÎºÎ ¿Ü»óÀÇ Á¤½Å°Ç°ÀÇÇÐÀû Æò°¡ ½Å»óÈ£(°í´ë¾È»êº´¿ø)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 09:35~10:00 °æµµ µÎºÎ ¿Ü»óÀÇ ÀÌÇØ Á¤±ÔÇÏ(°í´ë±¸·Îº´¿ø ½Å°æ¿Ü°ú)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 10:00~10:25 Á¤½Å°úÀû Áõ»óÀ» È£¼ÒÇÏ´Â µÎºÎ ¿Ü»ó ȯÀÚµéÀÇ °ü¸® ±èÁØÇü(°í´ë±¸·Îº´¿ø)
Åä·Ð 12-17 ÄÁº¥¼ÇȦ 10:25~10:40 Q & A ()
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 10:50~11:10 PTSD¿¡¼ stellate ganglion block À±¿ëÇö(ÀÎõÅ͹̳ÎÁ¤Çü¿Ü°ú)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 11:10~11:30 ºñ¸¸¿¡¼ ºñ°æ±¸¿ë ¾à¹° ¹× »ýÈ°½À°ü Á¶ÀýÀ» ÅëÇÑ °ü¸® ÃÖ¿øö(ÀÌ¿ÀÀÇ¿ø)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 11:30~11:50 »êÈÄ¿ì¿ïÁõ¿¡¼ brexanoloneÀÇ Àû¿ë È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 11:50~12:10 ³Ä¡¼º ƽÀå¾Ö¿¡¼ÀÇ DBS ÀÌÁ¤ÇÑ(¼¼ºê¶õ½ºº´¿ø)
Åä·Ð 12-17 ÄÁº¥¼ÇȦ 12:10~12:20 Q & A ()
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 12:20~12:50 Anxiety & Depression in the COVID Pandemia È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 12:50~13:20 Benefits of Agomelatine treatment strategies ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 13:30~13:55 Effects of antiepileptic drug on the mental health ÃÖÁØÈ£(ÇѾçÀÇ´ë)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 13:55~14:20 Effect of anti-tumor immunotherapy on the mental health ±è¼±¿µ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 14:20~14:45 Effect of antibiotics and antiviral agents on the mental health ±è¿øÇü(ÀÎÇÏÀÇ´ë)
Åä·Ð 12-17 ÄÁº¥¼ÇȦ 14:45~15:00 Q & A ()
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 15:10~15:30 ¸¶ÃëÅëÁõÀÇÇаú¿¡¼ º¸´Â ¸¸¼º ÅëÁõ °üÁ¡ ÃÖ»ó½Ä(°í´ë±¸·Îº´¿ø ¸¶ÃëÅëÁõÀÇÇаú)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 15:35~16:00 Somatic symptom disorder with predominant pain ¼½Â¿Ï(°µ¿¼º½Éº´¿ø)
±³À°½Ã°£ 12-17 ÄÁº¥¼ÇȦ 16:00~16:25 Psychiatric management of chronic pain ÀÌ°æȯ(±è¿ø¿í±â³äºÀ»ýº´¿ø)
Åä·Ð 12-17 ÄÁº¥¼ÇȦ 16:25~16:40 Q & A ()
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 09:10~09:35 Psychiatric Aspects of Parkinson¡¯s Disease Àӿ쿵(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 09:35~10:00 Psychiatric Aspects of Epilepsy ¾öÀ¯Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 10:00~10:25 Catatonia, Neuroleptic Malignant Syndrome, and Serotonin syndrome À̰Ǽ®(ÇѾçÀÇ´ë)
Åä·Ð 12-17 ´ëȸÀÇ½Ç 10:25~10:40 Q & A ()
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 10:50~11:15 Psychiatric Disorders during pregnancy and the postpartum period ½Åö¹Î(°í·ÁÀÇ´ë)
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 11:15~11:40 Psychiatric Symptoms and disorders in perimenopause ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 11:40~12:05 Premenstrual dysphoric disorder and psychotropic medications in Pregnancy °¿ø¼·(°æÈñÀÇ´ë)
Åä·Ð 12-17 ´ëȸÀÇ½Ç 12:05~12:20 Q & A ()
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 12:20~12:50 How to manage"Anhedonia and Emotional blunting" with Vortioxetine? °¿ø¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 12-17 ´ëȸÀÇ½Ç 12:50~13:20 When could Vortioxetine be a relevant treatment option? À̹®¼ö(°í·ÁÀÇ´ë)